Alison Gallafent
Corporate Officer/Principal bij E-THERAPEUTICS PLC
Oorsprong van het eerstegraads netwerk van Alison Gallafent
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Miscellaneous Commercial Services | 21 | |
| Public Company | Biotechnology | 6 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Alison Gallafent via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Biotechnology | Director/Board Member | |
Biothera, Inc.
 Biothera, Inc. Miscellaneous Commercial ServicesCommercial Services Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN. | Miscellaneous Commercial Services | Director/Board Member | |
| RENEURON GROUP PLC | Pharmaceuticals: Major | Chairman Chairman | |
ORA Capital Partners Ltd.
 ORA Capital Partners Ltd. Miscellaneous Commercial ServicesCommercial Services ORA Capital Partners Ltd. is a holding and management company whose principal activity is the development and growth of trading companies within its business portfolio. It is currently focused on technology, resources and financial services opportunities. The company operates through two segments: Business Portfolio Return & Advisory Fees and Financial Trading. The Business Portfolio Return & Advisory Fees segment represents gains and losses on the disposal and revaluation of portfolio investments held. The Financial Trading segment uses surplus cash for specific opportunities. It also engages in trading instruments and has smaller interests in a number of other companies. ORA Capital Partners was founded by Richard Ian Griffiths on November 7, 2005 and is headquartered in St. Peter Port, Guernsey. | Miscellaneous Commercial Services | Founder Director/Board Member | |
Woodbois Services Ltd
 Woodbois Services Ltd Other Metals/MineralsNon-Energy Minerals Woodbois Services Ltd. engages in the exploration and development of metal and minerals. The company primarily focuses on gold, nickel, copper, iron ore, and uranium. It has projects in Tanzania. The company was founded on December 20, 2007 and is headquartered in Surrey, the United Kingdom. | Other Metals/Minerals | Director/Board Member Director/Board Member | |
| Imperial College London | College/University | Doctorate Degree Doctorate Degree | |
Institute of Chartered Accountants in England & Wales
 Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Cambridge | College/University | Doctorate Degree Graduate Degree Graduate Degree | |
| MITHRA PHARMACEUTICALS S.A. | Pharmaceuticals: Major | Chief Executive Officer | |
| University of London | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| University of Bristol | College/University | Doctorate Degree | |
Leadiant Biosciences, Inc.
 Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| University College London | College/University | Doctorate Degree Graduate Degree | |
Merck Serono SA
 Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
| UK Stem Cell Foundation | Investment Trusts/Mutual Funds | Founder Founder | |
| DEEPMATTER GROUP PLC | Packaged Software | Chairman Chairman | |
Women in Bio, Inc.
 Women in Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Women in Bio, Inc. is an organization that supports women in the life sciences industry. The non-profit company is based in Bethesda, MD and has subsidiaries in the United States. The organization has 13 chapters in the United States and is funded by sponsors and partners who are dedicated to supporting diversity and inclusion for women of all ages. Founded in 2002, it offers professional educational programs, peer-to-peer learning, mentoring, and networking opportunities for women at all career levels. Women in Bio was founded by Faith L. Charles and Cynthia Wong Hu. | Miscellaneous Commercial Services | Director/Board Member | |
| PHARNEXT SCA | Biotechnology | Chief Executive Officer Director of Finance/CFO | |
Proteros biostructures GmbH
 Proteros biostructures GmbH Medical/Nursing ServicesHealth Services Proteros biostructures GmbH is a holding company which serves as a discovery service business. Its business areas are Discovery Pipeline, Discovery Services and Science & Technology. The Discovery Pipeline focuses on protein biochemistry, X-ray crystallography, biophysics, computational chemistry and property driven medicinal chemistry, Discovery Services offers drug discovery services with expertise and proprietary technologies for protein production, protein structure analysis, kinetic and thermodynamic profiling and Science & Technology segment focuses on industrialized structure-guided lead development infrastructure. The company was founded by Robert Huber and Torsten Neuefeind in 1999 and is headquartered in Martinsried, Germany. | Medical/Nursing Services | Director of Finance/CFO Chief Executive Officer | |
| ARDELYX, INC. | Pharmaceuticals: Major | Director/Board Member | |
| WOODBOIS LIMITED | Forest Products | Director/Board Member Director of Finance/CFO | |
Alborz Darou Pharmaceutical Co.
 Alborz Darou Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Alborz Darou Pharmaceutical Co. engages in the manufacture, and marketing of pharmaceutical products. It offers its formulations and products in the form of ampoules, tablets, suspensions, syrups, capsules, prefilled syringes, and soft liquids. The company was founded in 1976 and is headquartered in Tehran, Iran. | Pharmaceuticals: Major | Chief Executive Officer | |
| ADVICENNE | Pharmaceuticals: Generic | Chairman | |
| St Bartholomew's Hospital Medical College | College/University | Doctorate Degree | |
| DIMENSION THERAPEUTICS INC | Biotechnology | Chief Executive Officer | |
| Columbia University College of Physicians & Surgeons | College/University | Corporate Officer/Principal | |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Biotechnology | Chairman | |
| SAROSSA | Miscellaneous | Director/Board Member Chief Executive Officer | |
| AKARI THERAPEUTICS, PLC | Biotechnology | Chief Executive Officer | |
| The Cass Foundation | Director/Board Member | ||
Sund Capital ApS
 Sund Capital ApS Financial ConglomeratesFinance Sund Capital ApS provides investment services. The private company is based in Copenhagen, Denmark. | Financial Conglomerates | Chief Executive Officer | |
Pepgen Ltd.
 Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Packaged Software | Founder | |
Silence Therapeutics GmbH
 Silence Therapeutics GmbH BiotechnologyHealth Technology Part of Silence Therapeutics Plc, Silence Therapeutics GmbH is a German biotechnology company that develops RNAi-based drugs. The company is based in Berlin, Germany and was founded in 2014. | Biotechnology | Chief Executive Officer | |
Albumedix Ltd.
 Albumedix Ltd. BiotechnologyHealth Technology Part of Sartorius AG, Albumedix Ltd. is a British science-driven company and recognized leader of albumin-enabled solutions. The company, based in Nottingham, UK, was founded in 1984 with a mission to empower excellence. Albumedix has supported its life-science partners in delivering safe doses of clinical and marketed therapeutics. The company's solutions include the world's only USP-NF compliant recombinant human albumin, client-centric development and compliance services, and drug-enhancing technologies. By challenging the status quo and striving for more, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals. Albumedix is the world leader in recombinant human albumin and has developed a portfolio of products known as Recombumin®. Founded in 1973, the CEO of Albumedix is Jonas S. Moller. The company was acquired by Sartorius Stedim Biotech SA on September 30, 2022, for $500.47 million. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Ixaka Ltd.
 Ixaka Ltd. BiotechnologyHealth Technology Ixaka Ltd. engages in the development of advanced cell-based therapeutics for the treatment of critical limb ischemia. The company was founded by Gaby Salem and Vicente Saez Gonzalez in 2015 and is headquartered in London, the United Kingdom. | Biotechnology | Chairman | |
| PREMIER VETERINARY GROUP PLC | Agricultural Commodities/Milling | Chairman Comptroller/Controller/Auditor |
Statistieken
Internationaal
| Verenigd Koninkrijk | 25 |
| Verenigde Staten | 11 |
| Zwitserland | 4 |
| Frankrijk | 4 |
| Canada | 3 |
Sectoraal
| Health Technology | 25 |
| Consumer Services | 8 |
| Finance | 6 |
| Commercial Services | 5 |
| Non-Energy Minerals | 3 |
Operationeel
| Director/Board Member | 215 |
| Chairman | 74 |
| Corporate Officer/Principal | 68 |
| Independent Dir/Board Member | 39 |
| Chief Executive Officer | 30 |
Sterkste connecties
| Insiders | |
|---|---|
| Annalisa Jenkins | 51 |
| Andrew Richards | 44 |
| Iain Ross | 41 |
| Trevor Jones | 36 |
| Stephen Parker | 34 |
| Michael Bretherton | 33 |
| James Ede-Golightly | 29 |
| David Lemus | 22 |
| David Solomon | 22 |
| Eric Floyd | 18 |
| Lucio Iannone | 17 |
| Torsten Hoffmann | 9 |
| Steven Romano | 8 |
| Robert Quinn | 7 |
| Giles Campion | 7 |
- Beurs
- Insiders
- Alison Gallafent
- Bedrijfsconnecties